Skip to content
TrialMatch
Sign up
Recruiting Early Phase 1

CS-206 in Patients With Sickle Cell Disease

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.

Condition
Sickle Cell Disease
Tested
CS-206
Sponsor
CorrectSequence Therapeutics Co., Ltd

Who can join

Age
12 to 35 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 19

  • Minimum age: 12 years
  • Maximum age: 35 years
  • Study condition: Sickle Cell Disease
  • Participants must be between 12 to 35 years old (inclusive). Participants or their legal guardians (for participants below 18 years old) must provide written informed consent before any study-related procedures.
  • Participants must have a Documented βS/βS, βS/β0 or βS/β+ genotype.
  • Participants must have at least one of the following conditions
  • At least 2 occurrences of any of the following events within 2 years prior to screening.
  • Acute pain crisis: requiring a visit to a medical facility and administration of pain medications (opioids or intravenous NSAIDs) or red blood cell transfusions.
  • Acute chest syndrome: defined by the presence of a new pulmonary infiltrate on a chest X-ray, associated with pneumonia-like symptoms, including chest pain, fever, or respiratory distress.
  • Priapism lasting more than 2 hours and necessitating a visit to a medical facility for intervention.
  • Stroke or transient ischemic attack (TIA): confirmed by imaging studies (e.g., MRI or CT scan), including silent stroke, and overt stroke leading to neurological deficits lasting \>24 hours.
  • Presence of red cell alloimmunization (\>2 antibodies) and the need for ongoing chronic transfusions.
  • Participants who have failed, not tolerated, refused the standard of care for Sickle Cell Disease (SCD), or are unable to access the standard of care due to the availability
  • Other situations deemed appropriate for hematopoietic stem cell transplantation according to the sickle cell anemia treatment guidelines, as determined by the investigator.
  • Laboratory Parameters:
  • Documented Hemoglobin S (HbS) level ≥30% of total hemoglobin (Hb) concentration prior to transfusion.
  • HbF at screening \< 20%
  • Participants must have a Karnofsky Performance Status (KPS for participants above 16 years old, inclusive) or Lansky Play-Performance Scale (LPPS for participants below 16 years old) score of ≥70, indicating sufficient functional status to undergo the intervention.
  • Willing to comply with the protocol requirements, use contraception as required, attend regular follow-up visits, and cooperate with examinations.

Exclusion 15

  • Female participants who are pregnant, breastfeeding, or planning pregnancy during the study period are excluded.
  • Participation in another investigational drug trial within 30 days prior to screening or within 5 half-lives (whichever is longer).
  • Subjects who have received or are receiving luspatercept treatment within 3 months prior to screening.
  • Subjects who have previously received any gene therapy for the disease.
  • Subjects with a fully matched related donor who are already scheduled for allogeneic hematopoietic stem cell transplantation.
  • More than 10 unplanned hospitalizations or emergency visits within 12 months prior to screening, which the investigator believes are related to significant chronic pain rather than acute pain crisis (VOC).
  • Severe liver dysfunction:
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3× the upper limit of normal (ULN) or:
  • International Normalized Ratio (INR) \>1.5× ULN
  • Severe renal impairment (creatinine clearance \<30 mL/min/1.73 m²) are excluded.
  • Subjects with HIV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or Treponema pallidum infection during the screening period; those with active HBV or HCV infection; or known tuberculosis or parasitic infection, etc.
  • Excludes subjects with stable hepatitis B (HBV-DNA negative) after treatment and those cured of hepatitis C (HCV-RNA negative).
  • Known active bacterial, viral, or fungal infections.
  • Deemed unsuitable for autologous hematopoietic stem cell transplantation procedures as determined by the investigator.
  • Other situations deemed unsuitable for this study as determined by the investigator.

Where

1 site, 1 recruiting

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.